Theravance signs cardiovascular drug development deal with Merck

Merck & Co. and Theravance agreed to develop the latter's small molecule therapeutic candidates for hypertension and heart failure. The agreement grants Merck exclusive, worldwide rights to Theravance's drug candidates. Theravance will receive $5 million upfront and as much as $148 million in milestone fees for the initial indication plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN